chartexchange

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

GlobeNewswire Inc. | Sep 28, 2026 8:40 AM EDT

Chief Executive Officer Marc Hertz and Chief Scientific Officer Vipin Kumar to present on translating immune biology and clinical signals into novel therapeutic approaches for IPF

Read original article